Client award wins in 2014 have included
Most recently, Prosensa achieved the 2014 Scrip Awards for `Biotech Company of the Year´, having been shortlisted for this accolade for the previous three years. The Company has shown a dedication and focus on developing its portfolio of exon-skipping drugs for the treatment of Duchenne muscular dystrophy (DMD), to bring hope to boys for whom DMD is a debilitating and life shortening disease. Prosensa is engaged in the discovery and development of RNA-modulating therapeutics primary focusing on rare neuromuscular and neurodegenerative disorders.
At the end of November Premaitha Health was awarded with the `Bionow Investment Deal of the Year´. The award recognises the success of the completion of the Company’s reverse listing on the London Stock Exchange’s AIM. Premaitha Health is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.
In the Autumn, Gallus BioPharmaceuticals and GE Healthcare Life Sciences (NYSE: GE) were jointly recognised as winners of the BioProcess International (BPI) Award for Excellence in Facility Design and/or Retrofit for the successful design and construction of an advanced single-use biomanufacturing facility. The BPI awards, voted for by bioprocess experts and hosted by industry publication BioProcess International, recognize outstanding products, services, partnerships and people that have had the greatest positive impact across the biopharmaceutical manufacturing industry. Gallus and GE Healthcare together designed and built an advanced contract manufacturing facility in just nine months.
Oxford Gene Technology (OGT) was named as OBN’s Best Medtech Dealmaker for the second year in a row at the OBN awards in October. The award recognises OGT’s acquisition of Cambridge-based Cytocell Limited, a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer. OGT provides world-class genetics research solutions to leading clinical and academic research institutions and has helped pioneering the molecular medicine revolution by enabling smarter decision making in human healthcare.
NovaBiotics won three awards in 2014 reflecting its successful work on novel peptide antifungal and antibacterial therapeutics.
Dr Deborah O’Neil, the Company’s CEO, was named `E&Y UK Health Products & Services Entrepreneur of the Year 2014´. She founded NovaBiotics in 2004 and, over the past ten years, has worked to grow the business into a leading global biotechnology company. She received the award in recognition of her work to find cures and to combat resistance to antibiotics.
Earlier in the year she won the `Entrepreneur of the Year´ Award at the 2014 Grampian Awards for Business Excellence for her outstanding contribution to NovaBiotics, the industry sector and the wider economy. Both awards reflect Dr O’Neil´s role as a model in leadership and her track record of entrepreneurial success.
At the beginning of 2014 NovaBiotics was awarded the `Life Science Business Leadership´ award, which is presented to the business leader or management team by Scottish Enterprise that has significantly advanced their company in the previous year, with factors such as financing, partnerships, collaborations, achievement of milestones and growth being taken into consideration.
The Clinigen Group received the FDA’s first ever `Drug Shortage Assistance´ award in recognition of its contribution in addressing a US shortage of Foscavir® (foscarnet sodium) injection. Clinigen’s efforts related to the US shortage included making Foscavir® available on a named patient basis whilst acquiring the new drug application and submitting post-approval supplements to restart manufacturing with acceptable compliance records. These actions by Clinigen resolved a critical drug shortage affecting patients. This award also recognizes companies for their commitment to public health, as well as to quality manufacturing and is the first time the award has been made by the FDA.
Earlier in the year, Clinigen Group’s CEO Peter George received the European Mediscience `Chief Executive of the Year´ award. The judges recognized Peter George´s considerable achievements at the helm of the Clinigen Group since 2010 which include leading Clinigen through a successful listing on London Stock Exchange’s AIM in September 2012, the first in this sector for almost five years, and growing the Group significantly in only 5 years. The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK that is dedicated to delivering ‘the right drug, to the right patient at the right time’.
Mid-year Vaxxas was selected as `World Economic Forum Technology Pioneer´ 2015, which recognizes the significant potential of Vaxxas’ Nanopatch™ vaccines and immunotherapies. Vaxxas is one of 24 emerging technology companies from around the world and across all industries recognized for their potential to transform the future of business and society. Vaxxas is a biotechnology company enhancing the performance of existing and next-generation vaccines with its proprietary Nanopatch™ technology platform, which contains an ultra-high density array of very short projections that are dry-coated with vaccine.
In the spring, Hookipa Biotech was the winner of the `Best Financing Deal´ Award in the vaccine Industry Excellence (ViE) Awards 2014. The Award was in recognition of Hookipa’s €20 million ($27.6 million) Series B financing that closed in October 2013 and included existing investors Sofinnova Partners and Forbion Capital Partners as well as new investors Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners. Hookipa Biotech AG is developing a new class of innovative prophylactic and therapeutic vaccines based on its proprietary Vaxwave® technology, a novel vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer.
Commenting on the award successes, Sue Charles, Managing Partner, Life Sciences at Instinctif Partners said “These awards are a great testament to the progress our clients have made and their contribution to the life sciences sector as a whole. We play a small part in this success by supporting clients in identifying relevant awards and in the preparation of entries, where appropriate.”
“Congratulations to them all and also clients that have been shortlisted for awards in 2014” she added.
Instinctif Partners is a leading international business communications consultancy with an exceptionally strong focus in the Life Science sector. Its team is unique in that it has expertise across financial, corporate, healthcare and marketing communications, with an integrated design, branding and digital team. The Life Sciences practice also offers seamless global outreach with teams located in the UK, Germany, Australia and the US. Its client base spans pharma, biotechnology, medical devices, diagnostics, healthcare, laboratory supply and service providers in addition to venture capitalists, recruitment companies, not-for-profit, academic organisations and science-associated bodies.
For Further Information:
Managing Partner, Life Sciences
+44 (0)20 7457 2020
Sue CharlesManaging Partner